These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. Van Hove I; Hu TT; Beets K; Van Bergen T; Etienne I; Stitt AW; Vermassen E; Feyen JHM Prog Retin Eye Res; 2021 Nov; 85():100966. PubMed ID: 33775825 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema. Morjaria R; Chong NV Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1185-92. PubMed ID: 24856361 [TBL] [Abstract][Full Text] [Related]
10. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria]. Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675 [TBL] [Abstract][Full Text] [Related]
11. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE. Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914 [TBL] [Abstract][Full Text] [Related]
12. Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2009; 9(13):1-22. PubMed ID: 23074517 [TBL] [Abstract][Full Text] [Related]
13. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. Emerson MV; Lauer AK BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122 [TBL] [Abstract][Full Text] [Related]
14. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. Nesmith BL; Ihnen M; Schaal S Retina; 2014 Dec; 34(12):2423-30. PubMed ID: 25062438 [TBL] [Abstract][Full Text] [Related]
15. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema. Wong CW; Wong TT Br J Ophthalmol; 2019 Oct; 103(10):1356-1360. PubMed ID: 31040133 [TBL] [Abstract][Full Text] [Related]
17. Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection? Uyar E; Ulaş F; Alkan Y Curr Eye Res; 2021 Feb; 46(2):248-254. PubMed ID: 32635750 [TBL] [Abstract][Full Text] [Related]
18. [Results of the use of antioxidant and angioprotective agents in type 2 diabetes patients with diabetic retinopathy and age-related macular degeneration]. Moshetova LK; Vorob'eva IV; Alekseev IB; Mikhaleva LG Vestn Oftalmol; 2015; 131(3):34-44. PubMed ID: 26310005 [TBL] [Abstract][Full Text] [Related]
19. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744 [TBL] [Abstract][Full Text] [Related]
20. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Kiss S; Malangone-Monaco E; Wilson K; Varker H; Stetsovsky D; Smith D; Garmo V J Manag Care Spec Pharm; 2020 Mar; 26(3):253-266. PubMed ID: 32020843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]